Credit Suisse today posted its financial report for the third quarter of 2021.
Credit Suisse reported a pre-tax income of CHF 1.0 billion for the third quarter of 2021. The result benefited from a positive impact relating to Archegos of CHF 235 million, mainly due to a release of provision for credit losses pertaining to an assessment of the future recoverability of receivables, and gains on Credit Suisse’s equity investment in Allfunds Group of CHF 129 million.
The rise was partially offset by major litigation charges, including CHF 214 million related to the Mozambique matter as well as provisions for certain other legacy matters, including mortgage-related matters, and in connection with the SCFF matter.
Credit Suisse also recorded a further impairment of CHF 113 million relating to the valuation of its noncontrolling interest in York Capital Management.
Net income attributable to shareholders of CHF 434 million continued to be impacted by a significantly elevated effective tax rate, as previously guided, mainly due to only a partial tax recognition of the Archegos loss.
Wealth Management-related businesses reported net revenues of CHF 3.3 bn, up 3% year on year; on an adjusted basis, excluding significant items, net revenues were up 4%.
Investment Bank delivered a solid underlying performance despite continued discipline in risk and capital management with reductions to RWA and leverage exposure in Prime Services. Net revenues of USD 2.5 bn were up 10% year on year; IB reported results included a release of provision for credit losses of USD 202 mn (CHF 188 mn) as well as a USD 24 mn (CHF 23 mn) benefit to revenues and USD 26 mn (CHF 24 mn) net cost recovery in operating expenses relating to Archegos.
Sales & Trading revenues were down 13% year on year and Equity Sales & Trading revenues, excluding Archegos, were down 9% due to continued de-risking in Prime Services. Excluding Prime Services, Equity Sales & Trading revenues substantially increased driven by robust Equity Derivatives performance and higher Cash Equities results.
Capital Markets revenues were up 14% and Advisory revenues were up significantly, by 182%, year on year. Revenues in Global Trading Solutions, Credit Suisse’s collaboration between the IB and its wealth management businesses, declined, in part due to Credit Suisse’s reduced capital usage and more conservative risk appetite coupled with lower volumes and volatility compared to an exceptional comparable in 3Q20.
Operating expenses for the Group of CHF 4.6 bn increased by 6% year on year, mainly driven by higher litigation provisions and professional services fees; adjusted operating expenses, excluding significant items and Archegos, increased by 2% in part due to continued strategic investments across Credit Suisse’s businesses, including its investments in IT infrastructure, the build out of its mainland China business and the expansion of Private Banking coverage teams in APAC, as well as in risk and controls.
Credit Suisse continued to improve its capital ratios with a CET1 ratio of 14.4% at the end of 3Q21, compared to 13.7% at the end of 2Q21, and a CET1 leverage ratio of 4.3%, compared to 4.2% at the end of 2Q21. Its CET1 and leverage ratios benefitted from strong income generation and risk reduction across businesses.
Dear immortals, I need some wow gold inspiration to create.
Greetings! I’ve been following your web site for some time now and finally got the courage to go
ahead and give you a shout out from Houston Texas! Just wanted to tell you
keep up the excellent work!
zithromax antibiotics
how long does it take for metformin to work
is zoloft a maoi
flagyl sibo
is coughing a side effect of lisinopril
furosemide for dogs dosage
glucophage commercial
zithromax breastfeeding
gabapentin and melatonin
can amoxicillin cause diarrhea
cephalexin shelf life
escitalopram and hydroxyzine
cat gabapentin
ciprofloxacin drops for ears
bactrim dosage for uti adults
cephalexin and coffee
amoxicillin for sale
cephalexin vs keflex
bactrim over the counter cvs
oxalato de escitalopram
gralise vs neurontin
o que e ddavp
what is cozaar 100mg used for
depakote vs lamictal
citalopram 40 mg high
cozaar runner
ddavp bleeding dose
depakote price
can i drink on citalopram
augmentin pseudomonas
diclofenac brand name
diltiazem adverse effects
atorvastatin ezetimibe side effects
flomax dosage twice daily
cyclobenzaprine flexeril
reddit contrave
what is amitriptyline generic for
how to safely wean off daily aspirin
aripiprazole canada
allopurinol erectile dysfunction
how quickly does bupropion work
augmentin 875 125 mg
baclofen cerebral palsy
best time of day to take celebrex
buspirone tablets used
celexa pregnancy
ashwagandha weight loss reviews
celecoxib 200mg cap
acarbose wirkung
can you cut abilify 5mg in half
vitastir semaglutide reviews
actos leads
repaglinide diabetes prevention
protonix 40 mg tablet
soma vs robaxin
remeron vs seroquel
rybelsus and sitagliptin
spironolactone que es
synthroid fetus
ebay buy voltaren 2% topical solution
tizanidine a controlled substance
venlafaxine er 37.5 mg
tamsulosin canadian pharmacy
is zetia generic
zofran dosage kids
does wellbutrin help premature ejaculation
abilify and zyprexa
zofran and afib
zyprexa dopamine
cost of levitra
alternatives to cialis
levitra 20mg used for
cialis orders paypal paid
buy glucophage
Nice response in return of this question with genuine
arguments and telling the whole thing about that.
levitra for sale online
buy cialis in cro
brand levitra online pharmacy
cialis 10 mg
tramadol pharmacy cod
sildenafil citrate 100mg
rx crossroads pharmacy refill
cheap sildenafil
warfarin pharmacy protocol
tamoxifen pharmacy
cheapest sildenafil
Really no matter if someone doesn’t know after that its up to
other viewers that they will assist, so here it takes place.